MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD

Researchers at University Hospital Basel's Liechti Lab have received funding from MindMed to combine MDMA and LSD in a Phase 1 clinical trial. From the press release, "MDMA, an empathogen, is known to acutely induce feelings of increased well-being and trust. By combining LSD and MDMA within the same session ... MDMA may reduce some of the negative mood effects of LSD and make the patient more comfortable during psychedelic-assisted therapy."